Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
InMed Pharmaceuticals Inc. (INM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"InMed to Participate in Upcoming Virtual Investor Events Vancouver, BC – May 24, 2023 – InMed Pharmaceuticals Inc. , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the Company’ s executive team will be participating in the upcoming virtual investor events: Tribe Public Webinar Date: May 31, 2023 Time: 12:00 PM ET Registration: https://us06web.zoom.us/webinar/register/WN_6ZYkEADVSPOFd3g68IzQsw#/registration Eric A. Adams, CEO of InMed, and Jerry Griffin, VP, Sales and Marketing of BayMedica, will co-host a presentation event titled "Addressing The Increasing Demand For Rare Cannabinoids". Management will be available for a 5-10 minute Q&A session at the end of the presentation. Pleas..." |
|
| 05/19/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/16/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 12/12/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 11/17/2022 |
8-K
| Quarterly results |
| 11/17/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/26/2022 |
8-K
| Quarterly results |
| 09/29/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/23/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/20/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"FORM OF PRE-FUNDED WARRANT",
"FORM OF PREFERRED INVESTMENT OPTION",
"FORM OF PLACEMENT AGENT PREFERRED INVESTMENT OPTION",
"FORM OF SECURITIES PURCHASE AGREEMENT",
"FORM OF REGISTRATION RIGHTS AGREEMENT",
"InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market Vancouver, BC – September 9, 2022 – InMed Pharmaceuticals Inc. , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investors in the offering unregistered preferred investment options to purchase up to an aggregate of 1,382,490 common shares. The aggregate gross proceeds to the Company from the private placement is expected...",
"InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market Vancouver, BC – September 13, 2022 – InMed Pharmaceuticals Inc. , a leader in the research, development and manufacturing of rare cannabinoids, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share priced at-the-market under Nasdaq rules. In addition, the Company has issued to the investors in the offering unregistered preferred investment options to purchase up to an aggregate of 1,382,490 common shares. The aggregate gross proceeds to the Company from the private placement were approximately $6 million. The Company intend..." |
|
| 09/08/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/26/2022 |
8-K
| Material Modifications to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi... |
| 08/10/2022 |
8-K
| Resignation/termination of a director, Appointed a new director|
Docs:
|
"InMed Announces Changes to its Board of Directors Vancouver, BC – August 9, 2022 – InMed Pharmaceuticals Inc. , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public and private company management teams and boards to increase stakeholder value. She established and led healthcare groups at l..." |
|
| 07/26/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/15/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/10/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
|
|
|